Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. PTC
4. META
5. MSFT
6. SPY
7. GMAB
8. USO
9. GOOGL
10. AMD

Go back to Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 1c

Syros Reports Third Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

November 1, 2018 7:00 AM EDT

Opened Expansion Cohorts in Phase 1 Trial Evaluating SY-1365 in Multiple Ovarian and Breast Cancer Populations as Single Agent and in Combination

Selected Oral CDK7 Inhibitor SY-5609 as Development Candidate to Enter IND-Enabling Studies

Dose Escalation Data from Phase 1 Trial of SY-1365 to be Presented at EORTC-NCI-AACR and Initial Clinical Data from Combination Arms of Phase 2 Trial of SY-1425 to be Presented at ASH

Management to Host Conference Call at 7:30 AM ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:... More